• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放化疗后胰腺导管腺癌中三级淋巴器官的预后相关性。

Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.

机构信息

Department of Gastroenterological Surgery II, Faculty of Medicine, Hokkaido University, Sapporo, Japan.

Research Division of Genome Companion Diagnostics, Hokkaido University Hospital, Sapporo, Japan.

出版信息

Cancer Sci. 2019 Jun;110(6):1853-1862. doi: 10.1111/cas.14023. Epub 2019 May 9.

DOI:10.1111/cas.14023
PMID:30997706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6549910/
Abstract

The efficacy of preoperative neoadjuvant chemoradiotherapy (NAC) in cases of pancreatic cancer with extremely poor prognoses has been reported. In this study, we aimed to identify novel biomarkers that reflect prognoses following chemoradiotherapy using tertiary lymphoid organs (TLO) expressed in the tumor microenvironment. Resected tumor specimens were obtained from 140 pancreatic cancer patients. We retrospectively investigated the clinical relevance of TLO by categorizing patients into those who underwent upfront surgery (surgery first [SF]) and those who received NAC. The immunological elements within TLO were analyzed by immunohistochemistry (IHC). In the IHC analysis, the proportions of CD8+ T lymphocytes, PNAd+ high endothelial venules, CD163+ macrophages and Ki-67+ cells within the TLO were higher in the NAC group than in the SF group. In contrast, the proportion of programmed cell death-1+ immunosuppressive lymphocytes within TLO was lower in the NAC group than in the SF group. The NAC group demonstrated favorable prognoses compared with the SF group. In the multivariate analysis, the TLO/tumor ratio was determined as an independent predictive prognostic factor. In conclusion, the administration of preoperative chemoradiotherapy may influence the immunological elements in the tumor microenvironment and result in favorable prognoses in pancreatic ductal adenocarcinoma patients.

摘要

术前新辅助放化疗(NAC)在预后极差的胰腺癌病例中的疗效已有报道。在这项研究中,我们旨在使用肿瘤微环境中表达的三级淋巴器官(TLO)来确定反映放化疗后预后的新型生物标志物。从 140 名胰腺癌患者中获得了切除的肿瘤标本。我们通过将患者分为直接手术(手术优先 [SF])组和接受 NAC 组,回顾性地研究了 TLO 的临床相关性。通过免疫组织化学(IHC)分析 TLO 内的免疫成分。在 IHC 分析中,NAC 组 TLO 内的 CD8+T 淋巴细胞、PNAd+高内皮静脉、CD163+巨噬细胞和 Ki-67+细胞的比例高于 SF 组。相比之下,NAC 组 TLO 内程序性细胞死亡-1+免疫抑制淋巴细胞的比例低于 SF 组。与 SF 组相比,NAC 组显示出更好的预后。在多变量分析中,TLO/肿瘤比被确定为独立的预测预后因素。总之,术前放化疗的应用可能会影响肿瘤微环境中的免疫成分,并导致胰腺导管腺癌患者的预后良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/6549910/d32a751b953a/CAS-110-1853-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/6549910/4b0885757c1d/CAS-110-1853-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/6549910/3e4ecc83b8ec/CAS-110-1853-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/6549910/d32a751b953a/CAS-110-1853-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/6549910/4b0885757c1d/CAS-110-1853-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/6549910/3e4ecc83b8ec/CAS-110-1853-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/6549910/d32a751b953a/CAS-110-1853-g003.jpg

相似文献

1
Prognostic relevance of tertiary lymphoid organs following neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.新辅助放化疗后胰腺导管腺癌中三级淋巴器官的预后相关性。
Cancer Sci. 2019 Jun;110(6):1853-1862. doi: 10.1111/cas.14023. Epub 2019 May 9.
2
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.新辅助放化疗对局部可切除胰腺导管腺癌患者的免疫影响。
Ann Surg Oncol. 2014 Feb;21(2):670-6. doi: 10.1245/s10434-013-3390-y. Epub 2013 Dec 6.
3
The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.术前放化疗对胰腺癌肿瘤微环境的免疫影响。
Cancer Sci. 2021 Jul;112(7):2895-2904. doi: 10.1111/cas.14914. Epub 2021 May 19.
4
Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.胰腺导管腺癌中的浸润免疫细胞和基因突变。
Br J Surg. 2016 Aug;103(9):1189-99. doi: 10.1002/bjs.10187. Epub 2016 Jun 3.
5
MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy.新辅助放化疗后切除的可切除边缘胰腺癌中的MZB1
J Surg Res. 2017 Dec;220:391-401. doi: 10.1016/j.jss.2017.07.003. Epub 2017 Sep 3.
6
Ki67 expression and localization of T cells after neoadjuvant therapies as reliable predictive markers in rectal cancer.新辅助治疗后 Ki67 表达和 T 细胞定位可作为直肠癌可靠的预测标志物。
Cancer Sci. 2020 Jan;111(1):23-35. doi: 10.1111/cas.14223. Epub 2019 Dec 18.
7
Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.在胰腺导管腺癌中,CD8 + T淋巴细胞的上皮内攻击而非肿瘤内浸润是一个良好的预后指标。
Curr Mol Med. 2017;17(10):689-698. doi: 10.2174/1566524018666180308115705.
8
Low lymphocyte monocyte ratio after neoadjuvant therapy predicts poor survival after pancreatectomy in patients with borderline resectable pancreatic cancer.新辅助治疗后淋巴细胞单核细胞比值低提示边界可切除胰腺癌患者胰切除术后生存不良。
Surgery. 2019 Jun;165(6):1151-1160. doi: 10.1016/j.surg.2018.12.015. Epub 2019 Feb 11.
9
Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma.肿瘤内细胞邻里关系协调胰腺导管腺癌的结局。
Gastroenterology. 2024 Jun;166(6):1114-1129. doi: 10.1053/j.gastro.2024.01.013. Epub 2024 Jan 18.
10
Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells.新辅助治疗通过耗竭促肿瘤免疫细胞重塑胰腺癌微环境。
Clin Cancer Res. 2020 Jan 1;26(1):220-231. doi: 10.1158/1078-0432.CCR-19-1864. Epub 2019 Oct 4.

引用本文的文献

1
Multi-parametric MRI diffusion models combined with clinical information for predicting Ki-67 expression in pancreatic ductal adenocarcinoma: a prospective cohort study.多参数MRI扩散模型联合临床信息预测胰腺导管腺癌中Ki-67表达:一项前瞻性队列研究
Abdom Radiol (NY). 2025 Aug 29. doi: 10.1007/s00261-025-05164-8.
2
Investigating the correlation between tertiary lymphoid structures and clinical outcomes in pancreatic ductal adenocarcinoma: insights into tumor immunology.探究三级淋巴结构与胰腺导管腺癌临床结局之间的相关性:肿瘤免疫学见解
Front Oncol. 2025 Jun 26;15:1569947. doi: 10.3389/fonc.2025.1569947. eCollection 2025.
3

本文引用的文献

1
Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor Immunity, Immunosuppression, or Bystander Sentinels in Disease?癌症中的三级淋巴结构:抗肿瘤免疫、免疫抑制的驱动因素,还是疾病中的旁观者哨兵?
Front Immunol. 2017 Dec 19;8:1830. doi: 10.3389/fimmu.2017.01830. eCollection 2017.
2
B cells in tertiary lymphoid structures are associated with favorable prognosis in gastric cancer.三级淋巴结构中的B细胞与胃癌的良好预后相关。
J Surg Res. 2017 Jul;215:74-82. doi: 10.1016/j.jss.2017.03.033. Epub 2017 Apr 1.
3
Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Treatment of colorectal peritoneal metastases with oxaliplatin induces biomarkers predicting response to immune checkpoint blockade.
用奥沙利铂治疗结直肠腹膜转移可诱导预测免疫检查点阻断反应的生物标志物。
Transl Oncol. 2025 Sep;59:102464. doi: 10.1016/j.tranon.2025.102464. Epub 2025 Jul 1.
4
A novel approach to digital characterisation of Tertiary Lymphoid Structures in colorectal cancer.一种用于结直肠癌中三级淋巴结构数字表征的新方法。
Front Immunol. 2025 Jan 28;16:1500792. doi: 10.3389/fimmu.2025.1500792. eCollection 2025.
5
Editorial: Tertiary lymphoid structures (TLS) in the tumor immune microenvironment.社论:肿瘤免疫微环境中的三级淋巴结构(TLS)
Front Immunol. 2025 Jan 23;16:1555677. doi: 10.3389/fimmu.2025.1555677. eCollection 2025.
6
Landscape of B lymphocytes and plasma cells in digestive tract carcinomas.消化道癌中B淋巴细胞和浆细胞的情况
Ann Gastroenterol. 2025 Jan-Feb;38(1):1-11. doi: 10.20524/aog.2024.0936. Epub 2024 Dec 12.
7
Inhibitory effects of the combination of rapamycin with gemcitabine plus paclitaxel on the growth of pancreatic cancer tumors.雷帕霉素与吉西他滨加紫杉醇联合使用对胰腺癌肿瘤生长的抑制作用。
Hum Cell. 2025 Jan 11;38(2):44. doi: 10.1007/s13577-024-01165-9.
8
Unveiling immune resistance mechanisms in nasopharyngeal carcinoma and emerging targets for antitumor immune response: tertiary lymphoid structures.揭示鼻咽癌中的免疫抵抗机制及抗肿瘤免疫反应的新兴靶点:三级淋巴结构
J Transl Med. 2025 Jan 9;23(1):38. doi: 10.1186/s12967-024-05880-7.
9
Intratumoral high endothelial venules in solid tumors: a pooled study.实体瘤内高内皮静脉:荟萃研究。
Front Immunol. 2024 Jul 8;15:1401118. doi: 10.3389/fimmu.2024.1401118. eCollection 2024.
10
Tertiary lymphoid structures in cancer: maturation and induction.癌症中的三级淋巴结构:成熟与诱导。
Front Immunol. 2024 Apr 16;15:1369626. doi: 10.3389/fimmu.2024.1369626. eCollection 2024.
使用靶向深度测序检测评估KRAS、CDKN2A、TP53和SMAD4基因突变数量作为胰腺癌预后生物标志物的效用
Pancreas. 2017 Mar;46(3):335-340. doi: 10.1097/MPA.0000000000000760.
4
High Endothelial Venules and Lymphatic Vessels in Tertiary Lymphoid Organs: Characteristics, Functions, and Regulation.三级淋巴器官中的高内皮微静脉和淋巴管:特征、功能及调控
Front Immunol. 2016 Nov 9;7:491. doi: 10.3389/fimmu.2016.00491. eCollection 2016.
5
Antigen-Presenting Cells and Antigen Presentation in Tertiary Lymphoid Organs.三级淋巴器官中的抗原呈递细胞与抗原呈递
Front Immunol. 2016 Nov 7;7:481. doi: 10.3389/fimmu.2016.00481. eCollection 2016.
6
Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention.癌症中的三级淋巴结构:预后价值、调控及治疗干预的操控
Front Immunol. 2016 Oct 3;7:407. doi: 10.3389/fimmu.2016.00407. eCollection 2016.
7
Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers.三级淋巴结构,人类癌症抗肿瘤反应的推动者。
Immunol Rev. 2016 May;271(1):260-75. doi: 10.1111/imr.12405.
8
Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma.基质帕拉丁表达是胰腺导管腺癌的独立预后因素。
PLoS One. 2016 Mar 29;11(3):e0152523. doi: 10.1371/journal.pone.0152523. eCollection 2016.
9
Cancer statistics, 2016.癌症统计数据,2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
10
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.肿瘤相关三级淋巴结构中的调节性T细胞抑制抗肿瘤T细胞反应。
Immunity. 2015 Sep 15;43(3):579-90. doi: 10.1016/j.immuni.2015.08.006. Epub 2015 Sep 1.